NCT00707746View on ClinicalTrials.gov

Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

January 31, 2011

Conditions
Metabolic DiseasesHyperlipidemiasMetabolic DisorderHypercholesterolemiaDyslipidemiasLipid Metabolism Disorders
Interventions
DRUG

mipomersen

DRUG

placebo

Trial Locations (1)

1105AZ

Amsterdam

Sponsors
All Listed Sponsors
collaborator

Ionis Pharmaceuticals, Inc.

INDUSTRY

lead

Kastle Therapeutics, LLC

INDUSTRY